Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTOR: Rasagiline Tolerance in Early Parkinson's
NCT01048229Phase 4Terminated
- Sponsor
- Qualissima
- Start
- Oct 2008
- Primary completion
- Mar 2010
- Modality
- Irreversible Covalent Inhibitors
01
Overview
Phase 4, randomised, double-blind trial of rasagiline in Parkinson's disease (PD) (2 arms), sponsored by Qualissima. Primary endpoint: Percentage of patients presenting with at least one significant adverse event at 15 weeks. Started Oct 2008; status: terminated.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01048229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01048229.